Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN01941 in Healthy Volunteers

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN01941 in Healthy Volunteers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRN 01941 (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Crinetics Pharmaceuticals

Most Recent Events

  • 06 Apr 2020 According to an Crinetics Pharmaceuticals media release, the company has discontinued the development of CRN-01941 as Phase I data in healthy volunteers did not represent an improvement over paltusotine.
  • 06 Apr 2020 Status changed from recruiting to discontinued, according to an Crinetics Pharmaceuticals media release.
  • 13 Aug 2019 According to an Crinetics Pharmaceuticals media release, topline data from this trial is expceted in late 2019 or early 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top